Please assess the completion status of the following clinical trial:

Trial Title: Intravesical Liposomes for Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* • Written informed consent has been obtained~  * Males and females, at least 18 years of age~ * History of IC/PBS for at least 6 months documented in the medical record~ * Recurring IC/PBS symptoms~ * An average of 8 or more urine voids over a 3-day period, confirmed by the baseline voiding diary~ * Bladder pain score \> 4 in the last 24 hours (assessed at screening visit)~ * Previous use of medications and/or treatment(s) for symptom relief~ * Females of child-bearing capability agree to use a reliable form of birth control (condoms and/or oral contraceptives (birth control pills)) during the 4 week course of therapy and 1 week thereafter~ * Willing and capable of understanding and complying with all requirements of the protocol, including proper completion of the voiding diaries and self-administered questionnaires~Exclusion Criteria:~* • Subjects currently taking prescribed medications for IC/PBS will be able to continue the medications throughout the course of the study. If the patient cannot be maintained on a stable dose of the medication(s) throughout the treatment and follow-up period they will be excluded.~  * Subjects must not have had intravesical treatment(s)/bladder installations of the following medications: dimethylsulfoxide (DMSO), lidocaine and/or heparin within 1 month prior to study visit 1~ * Pregnant or lactating~ * History of bleeding diathesis~ * Currently on anticoagulant therapy (e.g. warfarin, clopidogrel)~ * Active bleeding peptic ulcer disease~ * Obvious neurological impairment which may be affecting bladder function~ * Known allergy to liposomes and/or egg yolk~ * Current or previous participation in another therapeutic or device study within 6 months of the screening visit~ * The presence of any clinically significant systemic disease or condition that in the opinion of the investigator would make the patient unsuitable for the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Liposomes (Type: EXPERIMENTAL): Liposomes

Based on this trial design, predict the completion outcome and termination type (if applicable).